Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer | Zendy

Gerhardt Attard | Zendy; Alison Reid | Zendy; Richard J. Auchus | Zendy; Beverly Hughes | Zendy; Amy Mulick | Zendy; Emilda Thompson | Zendy; Nikhil Babu Oommen | Zendy; Elizabeth Folkerd | Zendy; Mitch Dowsett | Zendy; Wiebke Arlt | Zendy; Johann S. de Bono | Zendy

Open Access

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

Author(s) -

Gerhardt Attard,

Alison Reid,

Richard J. Auchus,

Beverly Hughes,

Amy Mulick,

Emilda Thompson,

Nikhil Babu Oommen,

Elizabeth Folkerd,

Mitch Dowsett,

Wiebke Arlt,

Johann S. de Bono

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2189

Subject(s) - cyp17a1 , abiraterone acetate , endocrinology , prostate cancer , medicine , androgen , dihydrotestosterone , dexamethasone , chemistry , pharmacology , androgen deprivation therapy , cancer , hormone , enzyme , biochemistry

Abiraterone acetate is a small-molecule cytochrome P450 17A1 (CYP17A1) inhibitor that is active in castration-resistant prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research